These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34661653)

  • 1. Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study.
    Eroglu TE; Blom MT; Souverein PC; de Boer A; Tan HL
    Europace; 2022 Apr; 24(4):630-638. PubMed ID: 34661653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37 000 cases.
    Eroglu TE; Barcella CA; Blom MT; Mohr GH; Souverein PC; Torp-Pedersen C; Folke F; Wissenberg M; de Boer A; Schwartz PJ; Gislason GH; Tan HL;
    Br J Clin Pharmacol; 2022 Feb; 88(2):820-829. PubMed ID: 34374122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries.
    Eroglu TE; Mohr GH; Blom MT; Verkerk AO; Souverein PC; Torp-Pedersen C; Folke F; Wissenberg M; van den Brink L; Davis RP; de Boer A; Gislason GH; Tan HL
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):347-355. PubMed ID: 31504369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
    Das B; Rawat VS; Ramasubbu SK; Kumar B
    Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.
    Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE
    Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of out-of-hospital cardiac arrest in patients with rheumatoid arthritis: a nationwide study.
    Hegazy H; Folke F; Coronel R; Torp-Pedersen C; Gislason GH; Eroglu TE
    Open Heart; 2022 Jun; 9(1):. PubMed ID: 35649573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CredibleMeds
    Then MI; Andrikyan W; Maas R; Fromm MF
    Br J Clin Pharmacol; 2022 Jan; 88(1):226-236. PubMed ID: 34156728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of torsades de pointes risk drugs among patients with out-of-hospital cardiac arrest and likelihood of shockable rhythm and return of spontaneous circulation: A nationwide study.
    Krøll J; Jespersen CHB; Kristensen SL; Fosbøl EL; Vinding NE; Lippert F; Kragholm K; Jøns C; Hansen SM; Køber L; Jacobsen PK; Tfelt-Hansen J; Weeke PE
    Resuscitation; 2022 Oct; 179():105-113. PubMed ID: 35964772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
    Vieweg WV; Wood MA
    Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study.
    Pickham D; Helfenbein E; Shinn JA; Chan G; Funk M; Weinacker A; Liu JN; Drew BJ
    Crit Care Med; 2012 Feb; 40(2):394-9. PubMed ID: 22001585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study.
    Bakhriansyah M; Souverein PC; Klungel OH; de Boer A; Blom MT; Tan HL
    Europace; 2019 Jan; 21(1):99-105. PubMed ID: 30107407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid use is associated with increased out-of-hospital cardiac arrest risk among 40 000-cases across two countries.
    Eroglu TE; Barcella CA; Blom MT; Souverein PC; Mohr GH; Torp-Pedersen C; Folke F; Wissenberg M; de Boer A; Gislason GH; Tan HL;
    Br J Clin Pharmacol; 2022 May; 88(5):2256-2266. PubMed ID: 34837236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies].
    Vandael E; De WuLf I; Foulon V
    J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and determinants of QT interval prolongation in medical inpatients.
    Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
    Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
    Jardin CG; Putney D; Michaud S
    Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.